FP187 – Oral Immunomodulatory Dimethyl Fumarate (DMF)

Forward Pharma is focused on advancing its lead drug candidate FP187. The compound is based on the small molecule dimethylfumarate (DMF) in a patented controlled release erosion matrix tablet with enteric coating. FP187 is being developed for possible treatment of immune disorders including multiple sclerosis (Read more)